BRINEURA 150 mg/5 mL
- Medicine Name: Brineura
- API: Cerliponase alfa
- Dosage Form & Strength: Injection (2 vials of 150 mg/5 mL)
- Manufactured By: BioMarin Pharmaceutical Inc.
Brineura (cerliponase alfa) is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Recommended Dosage:
The recommended dosage of Brineura in pediatric patients is administered once every other week by intraventricular (IV) infusion, as prescribed and supervised by your doctor. This treatment should always be administered by qualified healthcare professionals in a clinical setting. Brineura is not recommended for patients who are less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age) or for patients weighing less than 2.5 kg.
If one or more doses are missed, treatment with Brineura should be restarted as soon as possible, as advised by your doctor, while maintaining the 2-week interval between infusions thereafter.
- Treatment with Brineura injection may cause serious hypersensitivity reactions, including anaphylaxis. Monitor patients closely during and after infusion. Symptoms may include rash, difficulty breathing, swelling, or low blood pressure. If severe reactions occur, immediately stop the infusion and provide appropriate medical treatment.
- Intraventricular access devices used for Brineura administration may increase the risk of meningitis or other infections. Monitor patients for vomiting, fever, headache, neck stiffness, or changes in consciousness. Prompt evaluation and treatment are necessary if infection is suspected.
- Complications related to the intraventricular device may include leakage, blockage, or device malfunction. These issues may affect proper medicine delivery. Regular device monitoring and appropriate maintenance are important to reduce complications and ensure safe administration of this therapy.
- Cardiovascular effects such as changes in heart rate or rhythm may occur during the infusion of Brineura. Monitor patients with appropriate clinical observation. If significant cardiovascular symptoms develop, clinicians should assess the patient and manage the condition accordingly.
- Infusion-associated reactions may occur during or shortly after administering this drug. Symptoms may include vomiting, fever, irritability, or skin reactions. Patients should be monitored during infusion. If reactions occur, treatment may be slowed, temporarily stopped, or managed with supportive care.
- There are limited data on the use of this medicine during pregnancy. The potential risks to the developing fetus are not fully known. Do not use this treatment during pregnancy only if the potential benefit justifies possible risks to the mother and fetus.
- It is not known whether Brineura is present in human breast milk. The effects on breastfed infants are also unknown. Healthcare providers should consider the benefits of breastfeeding along with the mother’s need for this treatment when making clinical decisions.
What documents are required to import BRINEURA to India?
BRINEURA (cerliponase alfa) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order get confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is BRINEURA available in India?
BRINEURA (cerliponase alfa injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input
- On the availability of Brineura in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Brineura price in India.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
- BRINEURA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of BRINEURA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).
Please contact +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for Brineura cost in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source BRINEURA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Brineura®?
Cerliponase alfa is the Generic Name for the trade name drug Brineura®.
What is the Manufacturer’s Name of Brineura®?
Brineura® is manufactured by BioMarin Pharmaceutical Inc.
Is Brineura approved by the FDA?
Yes. Brineura is approved by the FDA. Date of first approval: April 27, 2017.
What is the dosage and form of Brineura® supplied?
Brineura is supplied for Injection: 150 mg/5 mL (30 mg/mL) solution, two single-dose vials per carton co-packaged with Intraventricular Electrolytes Injection 5 mL in a single-dose vial for intraventricular use.
What are the most common side effects of Brineura® injection?
The most commonly reported side effects of Brineura® are seizures, pyrexia, ECG abnormalities, headache, decreased CSF protein, vomiting, device-related complications, feeling jittery, pleocytosis, hypersensitivity, increased CSF protein, hematoma, irritability, device-related infections, bradycardia, and hypotension.
How does Brineura Import in India work?
Brineura Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.
Who is a reliable Brineura supplier in India?
Indian Pharma Network is a trusted Brineura supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.
How much does Brineura® injection cost in India?
Brineura® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Brineura prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Brineura cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.
Can Brineura® injection be available in SAARC countries?
Apart from Gulf countries, Brineura® injection can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Brineura® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.
Is it safe to buy Brineura® injection online in India?
Yes, one can buy Brineura in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Brineura® injection through legal channels.
Who is an authorized Brineura importer in India?
Indian Pharma Network acts as a Brineura importer in India, assisting with Named Patient import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.
What are the storage conditions of Brineura® injection?
Store Brineura (cerliponase alfa) injection and intraventricular electrolytes injection upright in a freezer (-25°C to -15°C) in original carton to protect from light. Do not freeze.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.